Pharmaceutical Medicine

, Volume 26, Issue 4, pp 257–269

Forum

Update
  • 28 Downloads

References

References

  1. Food and Drug Administration. Report: FDA strengthens monitoring of post-approval drug safety [media release]. 2012 Apr 21[online]. Available from URL: http://www.fda.gov [Accessed 2012 May 16]

References

  1. European Medicine Agency. Comments invited on the ICH E2C (R2) guideline on periodic benefit-risk evaluation report [media release]. 2012 Apr 16 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2012 May 16]

References

  1. European Medicine Agency. Concept paper on the need for revision of the guideline on excipients in the label and package leaflet of medicinal products for human use (CPMP/463/00) — Draft. 2012 Feb 6 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2012 May 16]

References

  1. TGA — Therapeutic Goods Administration. Number of valid reports in adverse reactions database reaches 250,000 [media release]. 2012 Apr 4 [online]. Available from URL: http://www.tga.gov.au [Accessed 2012 May 16]

References

  1. Council of Europe. The Medicrime Convention. 2012 Mar 30 [online]. Available from URL: http://www.coe.int [Accessed 2012 May 16]

References

  1. Irish Patients Association. New study by the Irish patients association finds patient safety compromised. [media release]. 2012 Mar 2 [online]. Available from URL:http://irishpatients.ie [Accessed 2012 May 16]Google Scholar

References

  1. Song Z, Landon BE. Controlling health care spending: the Massachusetts experiment. N Eng J Med 2012; 366 (17): 1560–1CrossRefGoogle Scholar

References

  1. Kenneally M, Walshe V. Pharmaceutical cost-containment policies and sustainability: recent Irish experience. Value Health 2012; 15 (2): 389–93PubMedCrossRefGoogle Scholar

References

  1. Arthritis Foundation. Legislation may improve patient access to vital medications [media release]. 2012 Mar 20 [online]. Available from URL: http://www.arthritis.org [Accessed 2012 May 16]

References

  1. European Commission. Commission proposes faster access to medicines for patients [media release]. 2012 Mar 1 [online]. Available from URL: http://europa.eu [Accessed 2012 May 16]

References

  1. Fenton JJ, Jerant AF, Bertakis KD, et al. The cost of satisfaction: a national study of patient satisfaction, health care utilization, expenditures, and mortality. Arch Intern Med 2012; 172 (5): 405–11PubMedCrossRefGoogle Scholar

References

  1. Floyd JS, Heckbert SR, Weiss NS, et al. Use of administrative data to estimate the incidence of statin-related rhabdomyolysis. JAMA 2012; 307 (15): 1580–1582PubMedCrossRefGoogle Scholar

References

  1. American Geriatrics Society. New criteria identify commonly prescribed drugs that are potentially risky for older adults [media release]. 2012 Mar 1 [online]. Available from URL: http://www.americangeriatrics.org [Accessed 2012 May 16]

References

  1. Peluso MJ, Lewis SW, Barnes TR, et al. Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs. Br J Psychiatry 2012; 200: 387–92PubMedCrossRefGoogle Scholar

References

  1. El Marroun H, Jaddoe VWV, Hudziak JJ, et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psych. Epub 2012 Mar 5 [online]. Available from URL: http://dx.doi.org/10.1001/archgenpsychiatry.2011.2333 [Accessed 2012 May 16]

References

  1. Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012; 307 (13): 1414–1419PubMedCrossRefGoogle Scholar

References

  1. Chen C-H, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A. 2012 Apr 11 [online]. Available from URL: http://dx.doi.org/10.1073/pnas.1119920109 [Accessed 2012 May 16]

References

  1. Health Canada. Finasteride (Proscar, Propecia) and dutasteride (Avodart, Jalyn): may increase the risk of high-grade prostate cancer [media release]. 2012 Mar 19 [online]. Available from URL: http://www.hc-sg.gc.ca [Accessed 2012 May 16]

References

  1. American Academy of Pain Medicine. Study links the risk of hypogonadism in men to long acting opioids in patients using daily opioid therapy for chronic noncancer pain [media release]. 2012 Feb 24 [online]. Available from URL: http://www.painmed.org [Accessed 2012 May 16]

References

  1. Turbyville JC. Adverse reactions to subcutaneous allergen immunotherapy following thunderstorms [abstract no. 733]. 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology; 2012 Mar 2 [online]. Available from URL: http://annualmeeting.aaaai.org/[Accessed 2012 May 16]

References

  1. Gibbons RD, Hendricks Brown C, Hur K, et al. Suicidal thoughts and behavior with antidepressant treatment. Arch Gen Psych. Epub 2012 Feb 9 [online]. Available from URL: http://dx.doi.org/10.1001/archgenpsychiatry.2011.2048 [Accessed 2012 May 16]

References

  1. Hankin C, Cox L, Lang D, et al. Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids. Allergy Asthma Proc. Epub 2012 Apr 2 [online]. Available from URL: http://dx.doi.org/10.2500/aap.2012.33.3565 [Accessed 2012 May 16]

References

  1. Ubel PA, Berry SR, Nadler E, et al. In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival. Health Affairs 2012; 31 (4): 709–717PubMedCrossRefGoogle Scholar

References

  1. Johnston K, Levy AR, Lorigan P, et al. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study). Eur J Cancer. Epub 2012 Apr 3 [online]. Available from URL: http://dx.doi.org/10.1016/j.ejca.2012.03.003 [Accessed 2012 May 16]

References

  1. 1.
    Vulsteke C, Lambrechts D, Dieudonné AS, et al. Genetic variability in multi drug resistance protein 1 (abcc1/mrp1) and udp-glucuronosyltransferase-2b7 (ugt2b7) are highly correlated with severe haematological toxicity of adjuvant fec in breast cancer [abstract no. 415]. 8th European Breast Cancer Conference; 2012 Mar 21–24; Vienna [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  2. 2.
    European Cancer Organisation. Understanding individual genetic variation can help predict chemotherapy side effects [media release]. 2012 Mar 23 [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  3. 3.
    Linn S. Proffered paper. 70-gene signature prospectively predicts prognosis of patients with node-negative breast cancer: 5 year follow-up of the RASTER study [abstract no. 207]. 8th European Breast Cancer Conference; 2012 Mar 21–24; Vienna [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  4. 4.
    European Cancer Organisation. New genomic test spares patients chemotherapy with no adverse effect on survival [media release]. 2012 Mar 22 [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  5. 5.
    Nishimura R, Yamaguchi M, Watanabe R, et al. Lifestyle and change in bone mineral density in Japanese postmenopausal women with hormone receptor-positive breast cancer before and after 1 year of aromatase inhibitor treatment [abstract no. 370]. 8th European Breast Cancer Conference; 2012 Mar 21–24; Vienna [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  6. 6.
    Sato T, Muto I. Changes in bone mineral density during aromatase inhibitor therapy in post-menopausal breast cancer patients in Japan [abstract no. 361]. 8th European Breast Cancer Conference; 2012 Mar 21–24; Vienna [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  7. 7.
    European Cancer Organisation. Everolimus plus exemestane improves bone health in post-menopausal women [media release]. 2012 Mar 23 [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  8. 8.
    Schrijver LH, Rookus MA, Mooij TM, et al. BRCA1 carriers and oral contraceptives: risk-benefit calculation on breast and ovarian cancer [abstract no. 120]. 8th European Breast Cancer Conference; 2012 Mar 21–24; Vienna [online]. Available from URL: http://www.ecco-org.eu [Accessed 2012 May 16]
  9. 9.
    Neubauer H, Schneck H, Seeger H, et al. Overexpression of PGRMC1: a potential mechanism for increased breast cancer risk during combined treatment with estrogen and norethisterone [abstract no. 286]. 8th European Breast Cancer Conference; 2012 Mar 21–24; Vienna [online]. Available from URL: http://www.eccoorg.eu [Accessed 2012 May 16]

References

  1. 1.
    Cheang KI, Xu X, Veenstra TD, et al. Estradiol metabolites and changes in insulin sensitivity during oral contraceptive use [abstract no. PI-47].113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2012 Mar 14–17; Washington, DC [online]. Available from URL: http://www.nature.com/clpt/journal/v91/n1s/pdf/clpt2011359a.pdf [Accessed 2012 May 16]
  2. 2.
    Lee M, Chen Y, Shen C.A Prospective study of hla-b*5801 genotyping for the prevention of allopurinol induced severe cutaneous adverse reactions [abstract no. PIII-29]. 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2012 Mar 14–17; Washington, DC [online]. Available from URL: http://www.nature.com/clpt/journal/v91/n1s/pdf/clpt2011359a.pdf [Accessed 2012 May 16]
  3. 3.
    Lawler E, Altincatal A, Cho K, et al. Risk factors of severe thrombocytopenia following initiation of interferon-based therapy for the treatment of hepatitis-c among patients with diagnosed chronic liver disease [abstract no. PIII-11]. 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2012 Mar 14–17; Washington, DC [online]. Available from URL: http://www.nature.com/clpt/journal/v91/n1s/pdf/clpt2011359a.pdf [Accessed 2012 May 16]
  4. 4.
    Bowlin SJ, Xia F, Wang W, et al. Surveillance of drug metabolizing enzyme and transportor-based drug-drug interaction potential in patients receiving oral anti-neoplastic agents [abstract no. PII-18]. 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2012 Mar 14–17; Washington, DC [online]. Available from URL: http://www.nature.com/clpt/journal/v91/n1s/pdf/clpt2011359a.pdf [Accessed 2012 May 16]
  5. 5.
    Medco Health Solutions Inc. Medco study finds many patients on newer oncology treatments are at risk for drug interactions [media release]. 2012 Mar 16 [online]. Available from URL: http://www.medcohealth.com [Accessed 2012 May 16]

References

  1. 1.
    Klein EA, Thompson I, Tangen CM, et al. Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) [abstract no.7]. 2012 Genitourinary Cancers Symposium; 2012 Feb 2–4 [online]. Available from URL: http://www.asco.org/ascov2/meetings/abstracts?&;vmview=abst%5fdetail%5fview&confid=116&abstractid=89317 [Accessed 2012 May 16]
  2. 2.
    Efstathiou JA, Paulus R, Smith MR, et al. Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94–08 [abstract no. 18]. 2012 Genitourinary Cancers Symposium; 2012 Feb 2–4 [online]. Available from URL: http://www.asco.org/ascov2/meetings/abstracts?&;vmview=abst%5fdetail%5fview&confid=116&abstractid=89317 [Accessed 2012 May 16]
  3. 3.
    Suarez C, Morales R, Placer J, et al. Effect of chronic treatment of combined statins and aspirin on the risk of prostate cancer detection [abstract no. 185]. 2012 Genitourinary Cancers Symposium; 2012 Feb 2–4 [online]. Available from URL: http://www.asco.org/ascov2/meetings/abstracts?&;vmview=abst%5fdetail%5fview&confid=116&abstractid=89317 [Accessed 2012 May 16]
  4. 4.
    Cho E, Je Y, Choueiri TK. Analgesic use and the risk of renal cell carcinoma (RCC): results from a large up-to-date meta-analysis [abstract no. 395]. 2012 Genitourinary Cancers Symposium; 2012 Feb 2–4 [online]. Available from URL: http://www.asco.org/ascov2/meetings/abstracts?&;vmview=abst%5fdetail%5fview&confid=116&abstractid=89317 [Accessed 2012 May 16]
  5. 5.
    Richards CJ, Je Y, Schutz FAB, et al. Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors [abstract no. 349]. 2012 Genitourinary Cancers Symposium; 2012 Feb 2–4 [online]. Available from URL: http://www.asco.org/ascov2/meetings/abstracts?&;vmview=abst%5fdetail%5fview&confid=116&abstractid=89317 [Accessed 2012 May 16]

Copyright information

© Springer International Publishing AG 2012

Personalised recommendations